IVT PCV-25

IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine (PCV) developed by Inventprise to prevent invasive disease caused by *Streptococcus pneumoniae*, particularly in children and other vulnerable populations[1][2][5]. It is designed to provide broader protection than currently available vaccines by including capsular polysaccharides from 25 serotypes of *S. pneumoniae*, addressing both common and emerging strains responsible for serious infections such as pneumonia, sepsis, meningitis, and otitis media[1][6][7]. The vaccine uses a proprietary conjugation technology platform to enhance immunogenicity and coverage[8]. Its mechanism of action is immunostimulation through the induction of protective antibodies against the included serotypes[2][5].

Other names

25-valent pneumococcal conjugate vaccine